Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
285 results
  • Drugs for Acute Attack of Pediatric Migraine: A Network Meta-analysis of Randomized Controlled Trials. [Review]
    Clin Neurol Neurosurg. 2020 Apr 19; 195:105853.Wang G, Tan T, … Hong P
  • Migraine in pediatric is a common neurological disease, and its prevalence is varying widely. The medication for the acute attack of pediatric migraine is various. we take advantage of network meta-analysis to address the efficacy and rank of these medications. Database including Pubmed and Cochrane Library were queried using a specific searching strategy. The quality of trials enrolled was asses…
  • StatPearls: Triptans [BOOK]
    . StatPearls Publishing: Treasure Island (FL) Nicolas Samar S MCPHS University Nicolas Diala D Steward St. Elizabeth's Medical Center BOOK
  • Triptans are FDA approved and the first-line agents for the treatment of acute migraine episodes with or without aura.[1][2] There are seven triptans available in the United States in a variety of dosage forms: sumatriptan, naratriptan, zolmitriptan, rizatriptan, almotriptan, frovatriptan, and eletriptan.[3] Sumatriptan, in the subcutaneous formulation, is also approved for the treatment of clust…
  • Mucoadhesive buccal film of almotriptan improved therapeutic delivery in rabbit model. [Journal Article]
    Saudi Pharm J. 2020 Feb; 28(2):201-209.Nair AB, Al-Dhubiab BE, … Shehata TM
  • Administration of almotriptan as an oral therapy is largely limited because of poor aqueous solubility and rather low bioavailability. The aim of present investigation was to formulate oral mucoadhesive film of almotriptan to improve the drug delivery and desired therapeutic effects. Placebo films (F1-F8) were prepared by varying the concentrations of Proloc 15 (7.5-15% w/v) and Eudragit RL 100/R…
  • Pattern of triptans use: a retrospective prescription study in Calabria, Italy. [Journal Article]
    Neural Regen Res. 2020 Jul; 15(7):1340-1343.Scuteri D, Adornetto A, … Corasaniti MT
  • Triptans are 5-hydroxytryptamine 1B/1D receptor agonists used in moderate to severe migraine attacks as first line when non-specific, symptomatic, nonsteroidal anti-inflammatory drugs are not effective. To gain insight in the treatment of migraine in the regional context, this retrospective (from January to August of the years 2017 and 2018) study aimed at monitoring the use of triptans approved …
  • LiverTox: Clinical and Research Information on Drug-Induced Liver Injury: Migraine Headache Agents [BOOK]
    . National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda (MD)BOOK
  • Migraine headaches are marked by repeated, paroxysmal attacks of moderate-to-severe throbbing, one-sided headaches which (without treatment) last 4 to 72 hours and are usually associated with symptoms of nausea and vomiting. Migraine headaches are typically exacerbated by motion, bright lights and loud noises. Migraines may be associated with focal neurological symptoms referred to as “aura” whic…
  • StatPearls: Almotriptan [BOOK]
    . StatPearls Publishing: Treasure Island (FL) Sidhu Gursharan G Avalon University School of Medicine Patel Priti P Un of Florida College of Pharmacy BOOK
  • Almotriptan is the first FDA-approved drug used to treat migraine headaches in adults with or without an aura.[1] The drug is also useful in adolescents with a history of a migraine that, when left untreated, lasts 4 hours or longer. Certain triptan medications such as almotriptan and rizatriptan have also shown to be effective and safe for the management of acute migraines and other benign heada…
  • Almotriptan: a review of 20 years' clinical experience. [Journal Article]
    Expert Rev Neurother. 2019 08; 19(8):759-768.Pascual J, Vila C
  • Introduction: Almotriptan (ALT), a serotonin 5-HT1B/1D agonist has been used in the acute treatment of migraine with or without aura for 20 years, accumulating data on more than 15,000 patients in studies and from an estimated >150 million treated migraine attacks in daily clinical practice. The last major review of ALT was written almost 10 years ago. The current narrative review provides an ove…
  • Pharmacotherapy for acute migraines in children and adolescents. [Review]
    Expert Opin Pharmacother. 2019 03; 20(4):455-463.Barbanti P, Grazzi L, Egeo G
  • Migraine is increasingly recognized as an extremely burdensome and disabling disorder in both children and adolescents. A proper treatment plan is needed to improve the quality of life of both children and families as well as to minimize the risk of disease progression.
  • Network meta-analysis of migraine disorder treatment by NSAIDs and triptans. [Meta-Analysis]
    J Headache Pain. 2016 Dec; 17(1):113.Xu H, Han W, … Li M
  • CONCLUSIONS: This study suggests that eletriptan may be the most suitable therapy for migraine from a comprehensive point of view. In the meantime ibuprofen may also be a good choice for its excellent tolerability. Multi-component medication also attracts attention and may be a promising avenue for the next generation of migraine treatment.
  • Menstrual Migraine and Treatment Options: Review. [Review]
    Headache. 2017 Feb; 57(2):194-208.Maasumi K, Tepper SJ, Kriegler JS
  • CONCLUSIONS: MM can be very difficult to treat. For acute treatments, rizatriptan has the best overall evidence. For short-term prevention, frovatriptan, zolmitriptan, or naratriptan, as well as magnesium, estrogen, naproxen sodium, or dihydroergotamine may be useful.
  • Spotlight on frovatriptan: a review of its efficacy in the treatment of migraine. [Review]
    Drug Des Devel Ther. 2016; 10:3225-3236.Allais G, Benedetto C
  • Migraine is a common neurovascular disorder, affecting millions of people worldwide. Current guidelines recommend triptans as first-line treatment for moderate-to-severe migraine attacks. Frovatriptan is a second-generation triptan with a longer terminal elimination half-life in blood than other triptans (~26 hours). Three double-blind, randomized crossover preference studies have been recently c…
  • Comparative tolerability of treatments for acute migraine: A network meta-analysis. [Review]
    Cephalalgia. 2017 Sep; 37(10):965-978.Thorlund K, Toor K, … Goadsby PJ
  • Introduction Migraine headache is a neurological disorder whose attacks are associated with nausea, vomiting, photophobia and phonophobia. Treatments for migraine aim to either prevent attacks before they have started or relieve attacks (abort) after onset of symptoms and range from complementary therapies to pharmacological interventions. A number of treatment-related adverse events such as somn…
  • Newly Approved Agents for the Treatment and Prevention of Pediatric Migraine. [Review]
    CNS Drugs. 2016 09; 30(9):837-44.Kacperski J, Hershey AD
  • Treatment of pediatric migraine remains an unmet medical need. There continues to be a paucity of pediatric randomized controlled trials for the treatment of migraine, both in the acute and preventive settings. Pediatric studies are often complicated by high placebo-response rates and much of our current practice is based on adult trials. This lack of significant pediatric studies results in a wi…
  • Formulation Approaches of Triptans for Management of Migraine. [Review]
    Curr Drug Deliv. 2016; 13(6):882-98.Kassem AA
  • CONCLUSIONS: Utilizing alternative routes for triptans' administration in addition to designing appropriate formulations, were successful approaches. However, further investigations should be conducted to establish their bioavailability and in vitro- in vivo correlation studies are also required, to confirm the potential of the designed formulations for use in humans, hence novel efficient triptans' formulations may appear on the market in the near future.
  • Drugs for the acute treatment of migraine in children and adolescents. [Review]
    Cochrane Database Syst Rev. 2016 Apr 19; 4:CD005220.Richer L, Billinghurst L, … Hartling L
  • CONCLUSIONS: Low quality evidence from two small trials shows that ibuprofen appears to improve pain freedom for the acute treatment of children with migraine. We have only limited information on adverse events associated with ibuprofen in the trials included in this review. Triptans as a class are also effective at providing pain freedom in children and adolescents but are associated with higher rates of minor adverse events. Sumatriptan plus naproxen sodium is also effective in treating adolescents with migraine.
  • [Update on Current Care Guideline: Headache (children)]. [Journal Article]
    Duodecim. 2016; 132(2):187-8.HämäläInen M, Katri L, … Sätilä H
  • The majority of children with recurrent headaches can be effectively treated in the primary health care. Paracetamol and ibuprofen are the recommended first-line pain medications. Limited evidence is available on the effectiveness of triptans in children and adolescents. However, nasal sumatriptan and possibly oral rizatriptan and nasal zolmitriptan can be considered for children and adolescents,…
  • Acute Treatment Therapies for Pediatric Migraine: A Qualitative Systematic Review. [Review]
    Headache. 2016 Jan; 56(1):49-70.Patniyot IR, Gelfand AA
  • CONCLUSIONS: Of the available evidence, ibuprofen, prochlorperazine, and certain triptan medications are the most effective and safe agents for acute management of migraine and other benign headache disorders in the pediatric population. Additional studies in this population are needed, and should take into consideration variables such as dosing, co-administered medications, treatment duration, and length of treatment effect.
  • Acute Migraine Treatment. [Review]
    Continuum (Minneap Minn). 2015 Aug; 21(4 Headache):953-72.Becker WJ
  • CONCLUSIONS: NSAIDs and triptans are the mainstays of acute migraine therapy, and antiemetic drugs can be added as necessary. Opioids and combination analgesics containing opioids should not be used routinely. Patient-specific clinical features should help guide the selection of an acute medication for an individual patient. Acute medications can be organized into four treatment strategies for use in various clinical settings. The acetaminophen-NSAID strategy is suitable for patients with attacks of mild to moderate severity. The triptan strategy is suitable for patients with severe attacks and for those with attacks of moderate severity who do not respond well to NSAIDs. The refractory migraine strategies may be useful for patients who do not respond well to the NSAIDs or triptans alone and include using triptans and NSAIDs simultaneously in combination, DHE, and rescue medications (eg, dopamine antagonists, combination analgesics, and corticosteroids) when the patient's usual medications fail. Strategies for patients with contraindications to vasoconstricting drugs include use of NSAIDs, combination analgesics, and dopamine antagonists.Acetaminophen is the safest acute migraine drug during pregnancy, and acetaminophen with codeine is also an option. Sumatriptan may be an option during pregnancy for selected patients and is compatible with breast-feeding.
New Search Next